
Cancer cells have the ability to evade the immune system by down regulating the response to cancer cells. A new class of treatment, Immunotherapy with checkpoint inhibitors, such as PD1 or PDL1 antibodies can restore the immune system so that it can recognize and fight cancer cells.
MPDL3280A (also known as anti-PDL1) is an investigational monoclonal antibody designed to interfere with a protein called PD-L1. MPDL3280A is designed to target PD-L1 expressed on tumor cells and tumor-infiltrating immune cells. By inhibiting PD-L1, MPDL3280A may enable the activation of T cells, restoring their ability to effectively detect and attack tumor cells.
This antibody treatment is used in the OAK trial. Patient with lung cancer who have failed certain treatment s before, may be eligible. Patient either receive MPDL3280A or standard of care chemotherapy docetaxel (Taxotere) (A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "OAK) (For more information on clinicaltrials.gov click here)
For more information contact Irene, clinical research coordinator at 562-590-0345
MPDL3280A (also known as anti-PDL1) is an investigational monoclonal antibody designed to interfere with a protein called PD-L1. MPDL3280A is designed to target PD-L1 expressed on tumor cells and tumor-infiltrating immune cells. By inhibiting PD-L1, MPDL3280A may enable the activation of T cells, restoring their ability to effectively detect and attack tumor cells.
This antibody treatment is used in the OAK trial. Patient with lung cancer who have failed certain treatment s before, may be eligible. Patient either receive MPDL3280A or standard of care chemotherapy docetaxel (Taxotere) (A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "OAK) (For more information on clinicaltrials.gov click here)
For more information contact Irene, clinical research coordinator at 562-590-0345